Keros Therapeutics, Inc. (KROS)
11.07
-0.01
(-0.09%)
USD |
NASDAQ |
Sep 01, 12:01
Keros Therapeutics Cash from Operations (TTM) : -47.99M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -47.99M |
| March 31, 2026 | -57.20M |
| December 31, 2025 | 107.50M |
| September 30, 2025 | 88.79M |
| June 30, 2025 | 55.04M |
| March 31, 2025 | 44.86M |
| December 31, 2024 | -160.87M |
| September 30, 2024 | -140.32M |
| June 30, 2024 | -143.80M |
| March 31, 2024 | -134.83M |
| December 31, 2023 | -124.51M |
| September 30, 2023 | -120.49M |
| June 30, 2023 | -111.11M |
| March 31, 2023 | -102.87M |
| Date | Value |
|---|---|
| December 31, 2022 | -70.06M |
| September 30, 2022 | -68.18M |
| June 30, 2022 | -58.02M |
| March 31, 2022 | -53.07M |
| December 31, 2021 | -62.15M |
| September 30, 2021 | -50.57M |
| June 30, 2021 | -46.99M |
| March 31, 2021 | -39.28M |
| December 31, 2020 | -36.89M |
| September 30, 2020 | -34.40M |
| June 30, 2020 | -26.50M |
| March 31, 2020 | -21.60M |
| December 31, 2019 | -16.00M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Incyte Corp. | 1.980B |
| Nurix Therapeutics, Inc. | -293.70M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |